Advancements and challenges in immunotherapy for gastric cancer: current approaches and future directions
- PMID: 40469295
- PMCID: PMC12133846
- DOI: 10.3389/fimmu.2025.1592733
Advancements and challenges in immunotherapy for gastric cancer: current approaches and future directions
Abstract
Gastric cancer (GC) poses a major global health challenge, marked by high incidence and mortality rates. Conventional treatments such as surgery, chemotherapy, and targeted therapies show limited effectiveness in patients at advanced stages. As a result, immunotherapy has emerged as a promising strategy in the battle against cancer. In recent years, immunotherapy has flourished, with immune checkpoint inhibitors becoming widely applied in GC, while other immunotherapies are also rapidly advancing in clinical development, providing new therapeutic options for patients. The introduction of immunotherapy has profoundly changed the approach to GC treatment, with the expectation that additional immunotherapies will be developed in the near future. However, the clinical effectiveness of these therapies remains constrained due to the complexity of the tumor microenvironment (TME) in GC, the significant heterogeneity among patients, as well as the occurrence of immune therapy resistance and adverse reactions. This review provides an overview of recent advancements in GC immunotherapy, focusing on ICIs, adoptive cell therapy, and tumor vaccines. Key challenges such as patient selection, biomarker development, and combination therapy optimization are also discussed. In the future, a deeper exploration of the TME characteristics of GC and the implementation of personalized and precise immunotherapy are expected to further improve therapeutic outcomes and patient prognosis.
Keywords: adoptive cell therapy; gastric cancer; immune checkpoint inhibitors; immunotherapy; oncolytic viruses; tumor microenvironment; tumor vaccines.
Copyright © 2025 Zhang, Chen, Wei, Song, Zha, Wang and Xu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies.Biochim Biophys Acta Rev Cancer. 2025 Apr;1880(2):189277. doi: 10.1016/j.bbcan.2025.189277. Epub 2025 Feb 10. Biochim Biophys Acta Rev Cancer. 2025. PMID: 39938663 Review.
-
Immunotherapy of gastric cancer: Past, future perspective and challenges.Pathol Res Pract. 2021 Feb;218:153322. doi: 10.1016/j.prp.2020.153322. Epub 2020 Dec 24. Pathol Res Pract. 2021. PMID: 33422778 Review.
-
Advances in Immunotherapy and Targeted Therapy for Gastric Cancer: A Comprehensive Review.Br J Hosp Med (Lond). 2025 Mar 26;86(3):1-24. doi: 10.12968/hmed.2024.0759. Br J Hosp Med (Lond). 2025. PMID: 40135294 Review.
-
Application of immune checkpoint inhibitors and microsatellite instability in gastric cancer.World J Gastroenterol. 2024 Jun 7;30(21):2734-2739. doi: 10.3748/wjg.v30.i21.2734. World J Gastroenterol. 2024. PMID: 38899328 Free PMC article.
-
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.Mol Cancer. 2025 May 7;24(1):136. doi: 10.1186/s12943-025-02305-x. Mol Cancer. 2025. PMID: 40336045 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous